News brief­ing: Mer­ck picks up SHP2 op­tion from Tai­ho-As­tex deal; Taysha ex­pands part­ner­ship with UT South­west­ern

5 years ago
News Briefing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

5 years ago
Deals
Manufacturing

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out ...

5 years ago
People
Pharma

IDO on the re­bound? Dan­ish out­fit IO Biotech hopes so with over­sub­scribed Se­ries B one month af­ter BTD in melanoma

5 years ago
Financing

Adap­ti­m­mune 'ready for prime­time' as it pre­pares to launch T cell ther­a­py for sar­co­ma, CEO Adri­an Raw­cliffe says

5 years ago
Cell/Gene Tx
Manufacturing

A long­time Pfiz­er chief's ul­tra-qui­et biotech re-emerges with new cash and plans for the clin­ic

5 years ago
Startups

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Pharma
Cell/Gene Tx

Covid-19 roundup: Re­gen­eron scores $2.6B US sup­ply deal for an­ti­body cock­tail; Brazil­ian re­searchers walk back ...

5 years ago
Coronavirus

Bay­er wins pri­or­i­ty re­view for CKD pro­gram finerenone af­ter PhI­II da­ta showed a de­lay in dis­ease pro­gres­sion

5 years ago
FDA+

Flag­ship chris­tens the lat­est start­up to join the drug dis­cov­ery fleet, this time fo­cused on the lessons of cell ...

5 years ago
Startups

Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened ...

5 years ago
Deals
Cell/Gene Tx

Mon­cef Slaoui to step down from Op­er­a­tion Warp Speed in a month — re­port

5 years ago
Coronavirus

Am­gen ponies up $240M for Michi­gan dis­cov­ery out­fit's den­drit­ic cell tar­get­ing mol­e­cules for au­toim­mune dis­or­ders

5 years ago
Deals

With KRAS break­through on the hori­zon, Am­gen's David Reese re­flects on so­tora­si­b's loom­ing re­view date and murky ...

5 years ago
People
R&D

Spark co-founder Kathy High joins a long­time col­lab­o­ra­tor at AskBio, help­ing steer Bay­er's gene ther­a­py push

5 years ago
People
Cell/Gene Tx

News brief­ing: Ab­b­Vie se­lects first tar­get for Drag­on­fly part­ner­ship; Cog­ni­to nets BDD for Alzheimer's treat­ment ...

5 years ago
News Briefing

Mer­ck snags pri­or­i­ty re­view for Pre­vnar 13 ri­val — just one month af­ter Pfiz­er sent its fol­low-on to the FDA

5 years ago
FDA+

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

5 years ago
Pharma

Abzena plots 6th bi­o­log­ics plant as de­mand for mam­malian cell-line pro­duc­tion con­tin­ues to grow

5 years ago
Manufacturing

Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for com­bi­na­tion tri­al

5 years ago
R&D

Covid-19 roundup: Trump ad­min­is­tra­tion plan­ning to speed up shots; EMA to re­view As­traZeneca/Ox­ford vac­cine

5 years ago
Coronavirus

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

5 years ago
Deals
AI

Once aim­ing to dou­ble on­col­o­gy pipeline, Servier's US branch touts rapid pace in build­ing its foothold in the space

5 years ago
Manufacturing

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

5 years ago
Deals
First page Previous page 756757758759760761762 Next page Last page
A service from the Financial Times